Clinical UM Guideline |
Subject: Maternity Ultrasound in the Outpatient Setting | |
Guideline #: CG-MED-42 | Publish Date: 01/03/2024 |
Status: Reviewed | Last Review Date: 11/09/2023 |
Description |
This document addresses the use of maternity ultrasound in the outpatient setting. This document does not address nuchal translucency.
Note: Please see the following related document for additional information:
Clinical Indications |
Medically Necessary:
Maternity ultrasound is considered medically necessary for any of the following:
Not Medically Necessary:
Maternity ultrasound is considered not medically necessary for:
Coding |
The following codes for treatments and procedures applicable to this guideline are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.
When services are Medically Necessary for routine anatomy screen and dating when criteria are met:
CPT |
|
76801-76802 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, first trimester (< 14 weeks, 0 days), transabdominal approach; single or first gestation/each additional gestation [includes codes 76801, 76802] |
76805-76810 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, after first trimester (> 14 weeks 0 days), transabdominal approach; single or first gestation/each additional gestation [includes codes 76805, 76810] |
76811-76812 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation plus detailed fetal anatomic examination, transabdominal approach; single or first gestation/each additional gestation [includes codes 76811, 76812] |
76815 | Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses |
76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up (eg, re-evaluation of fetal size by measuring standard growth parameters and amniotic fluid volume, re-evaluation of organ system(s) suspected or confirmed to be abnormal on a previous scan), transabdominal approach, per fetus |
76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
|
|
ICD-10 Diagnosis |
|
| For any of the diagnosis codes listed below for abnormalities and high-risk conditions, and including the following: |
Z34.00-Z34.93 | Encounter for supervision of normal pregnancy [codes 76801, 76805, when criteria are met] |
Z36.0-Z36.9 | Encounter for antenatal screening of mother |
When services may be Medically Necessary when criteria are met for known or suspected abnormality of maternal reproductive structure, fetus, or placenta, or fetal viability or other high-risk conditions:
For the procedure codes listed above for the following diagnoses
ICD-10 Diagnosis |
|
A92.5 | Zika virus disease |
D25.0-D25.9 | Leiomyoma of uterus |
O00.00-O00.91 | Ectopic pregnancy |
O01.0-O01.9 | Hydatidiform mole |
O02.0-O02.9 | Other abnormal products of conception |
O03.4 | Incomplete spontaneous abortion without complication |
O03.9 | Complete or unspecified spontaneous abortion without complication |
O07.4 | Failed attempted termination of pregnancy without complication |
O09.00-O09.03 | Supervision of pregnancy with history of infertility |
O09.10-O09.13 | Supervision of pregnancy with history of ectopic pregnancy |
O09.A0-O09.A3 | Supervision of pregnancy with history of molar pregnancy |
O09.211-O09.219 | Supervision of pregnancy with history of pre-term labor |
O09.291-O09.299 | Supervision of pregnancy with other poor reproductive or obstetric history |
O09.30-O09.33 | Supervision of pregnancy with insufficient antenatal care |
O09.511-O09.529 | Supervision of elderly primigravida and multigravida |
O09.811-O09.93 | Supervision of other or unspecified high risk pregnancy |
O10.011-O10.019 | Pre-existing essential hypertension complicating pregnancy |
O10.111-O10.119 | Pre-existing hypertensive heart disease complicating pregnancy |
O10.211-O10.219 | Pre-existing hypertensive chronic kidney disease complicating pregnancy |
O10.311-O10.319 | Pre-existing hypertensive heart and chronic kidney disease complicating pregnancy |
O10.411-O10.419 | Pre-existing secondary hypertension complicating pregnancy |
O10.911-O10.919 | Unspecified pre-existing hypertension complicating pregnancy |
O11.1-O11.3 | Pre-existing hypertension with pre-eclampsia; first, second or third trimester |
O11.9 | Pre-existing hypertension with pre-eclampsia; unspecified trimester |
O14.00-O14.03 | Mild to moderate pre-eclampsia; unspecified, second or third trimester |
O14.10-O14.13 | Severe pre-eclampsia; unspecified, second or third trimester |
O14.20-O14.23 | HELLP syndrome; unspecified, second or third trimester |
O14.90-O14.93 | Unspecified pre-eclampsia; unspecified, second or third trimester |
O16.1-O16.3 | Unspecified maternal hypertension; first, second or third trimester |
O16.9 | Unspecified maternal hypertension; unspecified trimester |
O20.0-O20.9 | Hemorrhage in early pregnancy |
O21.0-O21.9 | Excessive vomiting in pregnancy |
O24.011-O24.019 | Pre-existing diabetes mellitus, type 1, in pregnancy |
O24.111-O24.119 | Pre-existing diabetes mellitus, type 2, in pregnancy |
O24.311-O24.319 | Unspecified pre-existing diabetes mellitus in pregnancy |
O24.410-O24.419 | Gestational diabetes mellitus in pregnancy |
O24.811-O24.819 | Other pre-existing diabetes mellitus in pregnancy |
O24.911-O24.919 | Unspecified diabetes mellitus in pregnancy |
O26.20-O26.23 | Pregnancy care for patient with recurrent pregnancy loss |
O26.30-O26.33 | Retained intrauterine contraceptive device in pregnancy |
O26.841-O26.849 | Uterine size-date discrepancy complicating pregnancy |
O26.851-O26.859 | Spotting complicating pregnancy |
O26.872-O26.879 | Cervical shortening |
O30.001-O30.93 | Multiple gestation |
O31.00X0-O31.8X99 | Complications specific to multiple gestation |
O32.0XX0-O32.9XX9 | Maternal care for malpresentation of fetus |
O33.0-O33.9 | Maternal care for disproportion |
O34.00-O34.93 | Maternal care for abnormality of pelvic organs |
O35.00X0-O35.9XX9 | Maternal care for known or suspected fetal abnormality and damage |
O36.0110-O36.0999 | Maternal care for anti-D [Rh] antibodies |
O36.20X0-O36.23X9 | Maternal care for hydrops fetalis |
O36.4XX0-O36.4XX9 | Maternal care for intrauterine death |
O36.5110-O36.5999 | Maternal care for known or suspected poor fetal growth |
O36.60X0-O36.63X9 | Maternal care for excessive fetal growth |
O36.70X0-O36.73X9 | Maternal care for viable fetus in abdominal pregnancy |
O36.80X0-O36.80X9 | Pregnancy with inconclusive fetal viability |
O36.8120-O36.8199 | Decreased fetal movements |
O36.8310-O36.8399 | Maternal care for abnormalities of the fetal heart rate or rhythm |
O36.8910-O36.8999 | Maternal care for other specified fetal problems |
O36.90X0-O36.93X9 | Maternal care for fetal problem, unspecified |
O40.1XX0-O40.9XX9 | Polyhydramnios |
O41.00X0-O41.93X9 | Other disorders of amniotic fluid and membranes |
O42.00-O42.92 | Premature rupture of membranes |
O43.021-O43.029 | Fetus-to-fetus placental transfusion syndrome |
O43.101-O43.199 | Malformation of placenta |
O43.211-O43.93 | Morbidly adherent placenta, other/unspecified placental disorder |
O44.00-O44.53 | Placenta previa |
O45.001-O45.93 | Premature separation of placenta (abruptio placentae) |
O46.001-O46.93 | Antepartum hemorrhage |
O47.00-O47.9 | False labor |
O48.0-O48.1 | Late pregnancy |
O60.00-O60.03 | Preterm labor without delivery |
O73.0-O73.1 | Retained placenta and membranes, without hemorrhage |
O76 | Abnormality in fetal heart rate and rhythm complicating labor and delivery |
O98.111-O98.119 | Syphilis complicating pregnancy |
O99.210-O99.213 | Obesity complicating pregnancy |
O99.310-O99.313 | Alcohol use complicating pregnancy |
O99.320-O99.323 | Drug use complicating pregnancy |
O99.330-O99.333 | Smoking (tobacco) complicating pregnancy |
O99.810 | Abnormal glucose complicating pregnancy |
O99.891 | Other specified diseases and conditions complicating pregnancy |
Q51.21-Q51.28 | Other doubling of uterus |
Z20.821 | Contact with and (suspected) exposure to Zika virus |
When services are Not Medically Necessary:
For the procedure and diagnosis codes listed above when criteria are not met or for all other diagnoses not listed; or when the code describes a procedure or situation designated in the Clinical Indications section as not medically necessary.
Discussion/General Information |
Ultrasound imaging, also called ultrasound scanning or sonography, is a method of obtaining images of internal organs by sending high-frequency sound waves into the body. The sound wave echoes are recorded and displayed as a real-time visual image. No ionizing radiation (x-ray) is used in ultrasound imaging. Ultrasound during pregnancy is used to assess the uterus, umbilical cord and placenta, as well as fetal anatomy and well-being. Ultrasound imaging can be used after delivery to evaluate abnormalities of the reproductive and adjacent structures.
The American College of Obstetricians and Gynecologists (ACOG) 2018 Practice Bulletin Ultrasound in Pregnancy lists the following recommendations:
The following conclusions are based on good and consistent evidence (Level A):
The following conclusions are based on limited or inconsistent evidence (Level B):
The following conclusion and recommendation are based primarily on consensus and expert opinion (Level C):
The American College of Radiology (ACR), the American Institute of Ultrasound in Medicine (AIUM), ACOG, the Society for Maternal Fetal Medicine (SMFM), and the Society of Radiologists in Ultrasound (SRU) practice parameter (2018) notes:
A standard obstetrical ultrasound examination in the first trimester includes evaluation of the presence, size, location, and number of gestational sac(s). The gestational sac is examined for the presence of yolk sac and embryo/fetus (a fetus is generally defined as greater than or equal to 10 weeks gestational age). When an embryo/fetus is detected, it should be measured, and the cardiac activity should be recorded by 2-D video clip or M-mode. The routine use of pulsed Doppler ultrasound to either document or “listen” to embryonic/fetal cardiac activity is discouraged. The uterus, cervix, adnexa, and cul-de-sac region should be examined.
An obstetrical ultrasound in the second or third trimester includes an evaluation of fetal number, cardiac activity, presentation, amniotic fluid volume, placental position, fetal biometry, and an anatomic survey. The maternal cervix and adnexa should be examined.
Zika virus was first reported in South America in May 2015 and since that time has now appeared in the United States. In 2016, ACOG and the SMFM released a practice advisory regarding the current information and recommendations regarding the Zika virus. The recommendations are based on limited data. In October 2017, ACOG and SMFM released an updated version of the practice advisory based upon updated Centers for Disease Control and Prevention (CDC) recommendations and recently published guidance. Recommendations for the management of a pregnant individuals with suspected Zika virus infection include:
The 2021 CDC guideline on the treatment of sexually transmitted infections includes management recommendations for individuals who are diagnosed with syphilis in the second half of pregnancy. In addition to treatment, these individuals should undergo a sonographic fetal evaluation to evaluate for signs of fetal or placental syphilis.
While there is no reliable evidence to support ultrasounds performed during pregnancy will harm a fetus, there is general agreement that the casual use of ultrasonography during pregnancy should be avoided (ACOG, 2018). The 2018 ACR/AIUM/ACOG/SMFM/SRU practice parameter notes “Obstetrical ultrasound should be performed only when there is a valid medical reason, and the lowest possible ultrasonic exposure settings should be used to gain the necessary diagnostic information.”
Definitions |
Ultrasound: A screening or diagnostic technique in which very high frequency sound waves are passed into the body, and the reflected echoes are detected and analyzed to build a picture of the internal organs or of a single fetus or multiple fetuses in the uterus.
References |
Peer Reviewed Publications:
Government Agency, Medical Society, and Other Authoritative Publications:
Websites for Additional Information |
Index |
Maternal Ultrasound
Obstetric
Prenatal
Sonography
History |
Status | Date | Action |
Reviewed | 11/09/2023 | Medical Policy & Technology Assessment Committee (MPTAC) review. Updated References sections. |
Revised | 11/10/2022 | MPTAC review. Replaced term “women” with “individual” within clinical indications. Updated Discussion and References section. Updated Coding section; added ICD-10-CM code ranges O98.111-O98.119, O99.310-O99.313, O99.320-O99.323, O99.330-O99.333. |
| 09/28/2022 | Updated Coding section with 10/01/2022 ICD-10-CM changes; added O35.00X0-O35.9XX9 replacing O35.0XX0-O35.9XX9. |
Reviewed | 11/11/2021 | MPTAC review. Updated References section. Reformatted Coding section. |
Reviewed | 11/05/2020 | MPTAC review. Updated References and Websites for additional information sections. Reformatted Coding section. |
| 10/01/2020 | Updated Coding section with 10/01/2020 ICD-10-CM changes; added O99.891; removed Q51.20 deleted 09/30/2020. |
| 04/01/2020 | Updated Coding section; corrected ICD-10 diagnosis code O41.00X0. |
Revised | 11/07/2019 | MPTAC review. Updated grammar in medically necessary statement regarding maternal risk factors from “including but not limited to, hypertension, diabetes, sickle cell disease preeclampsia), substance abuse, or hyperemesis gravidarum” to “including but not limited to, hypertension, diabetes or sickle cell disease), preeclampsia, substance abuse or hyperemesis gravidarum”. Updated Discussion, References and Websites for Additional Information sections. |
| 10/01/2019 | Updated Coding section to add ICD-10-CM diagnosis codes O09.00-O09.03, O09.811-O09.829. |
Reviewed | 01/24/2019 | MPTAC review. Updated Discussion/General Information, References and Websites for Additional Information sections. Updated Coding section with additional diagnosis codes D25.0-D25.9, O26.872-O26.879, O99.210-O99.213, O99.810. |
| 09/20/2018 | Updated Coding section with 10/01/2018 ICD-10-CM diagnosis code changes; added Q51.20-Q51.28, Z20.821. |
| 04/25/2018 | Updated Coding section to include ICD-10-CM diagnosis codes Z36.0-Z36.9. |
Reviewed | 02/27/2018 | MPTAC review. The document header wording updated from “Current Effective Date” to “Publish Date.” Updated Discussion/General Information, References and Websites for Additional Information sections. |
| 10/01/2017 | Updated Coding section with 10/01/2017 ICD-10-CM diagnosis code changes. |
Revised | 02/02/2017 | MPTAC review. Added medically necessary indication when there is a known or suspected exposure to the Zika virus to the Clinical Indications section. Added Websites for Additional Information section. Updated Discussion/General Information, Coding and Reference sections. |
| 10/01/2016 | Updated Coding section with 10/01/2016 ICD-10-CM diagnosis code changes. |
Reviewed | 02/04/2016 | MPTAC review. Updated Discussion/General Information and Reference sections. Removed ICD-9 codes from Coding section. |
Reviewed | 02/05/2015 | MPTAC review. Updated Coding, Description, Discussion/General Information, and References. |
Revised | 02/13/2014 | MPTAC review. Addition of “cell-free fetal deoxyribonucleic acid (DNA) screening for aneuploidy” to Medically Necessary Statement. Clarification to Not Medically Necessary Statement. Updated References. |
New | 02/14/2013 | MPTAC review. Initial document development. |
Federal and State law, as well as contract language, and Medical Policy take precedence over Clinical UM Guidelines. We reserve the right to review and update Clinical UM Guidelines periodically. Clinical guidelines approved by the Medical Policy & Technology Assessment Committee are available for general adoption by plans or lines of business for consistent review of the medical necessity of services related to the clinical guideline when the plan performs utilization review for the subject. Due to variances in utilization patterns, each plan may choose whether to adopt a particular Clinical UM Guideline. To determine if review is required for this Clinical UM Guideline, please contact the customer service number on the member's card.
Alternatively, commercial or FEP plans or lines of business which determine there is not a need to adopt the guideline to review services generally across all providers delivering services to Plan’s or line of business’s members may instead use the clinical guideline for provider education and/or to review the medical necessity of services for any provider who has been notified that his/her/its claims will be reviewed for medical necessity due to billing practices or claims that are not consistent with other providers, in terms of frequency or in some other manner.
No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.
© CPT Only - American Medical Association